Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma—rationale for targeting ARID1A deficiency

Abstract excerpt

Background Gastric adenocarcinoma (GAC) is a lethal disease with limited therapeutic options. Genetic alterations in chromatin remodelling gene AT-rich interactive domain 1A ( ARID1A ) and mTOR pathway activation occur frequently in GAC. Targeting the mechanistic target of rapamycin (mTOR) pathway in unselected patients has failed to show survival benefit. A deeper understanding of GAC might identify a subset...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chromatin Remodeling and Cancer
• Share to Mechanisms of cancer metastasis
• Share to Neuroendocrine Tumor Research Advances